Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go?
Qiuyao Huang, Yan Zhong, Hui Dong, et al.
European Journal of Medicinal Chemistry (2019) Vol. 187, pp. 111922-111922
Closed Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Azucena Salas, Cristian Hernández-Rocha, Marjolijn Duijvestein, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 6, pp. 323-337
Closed Access | Times Cited: 474
IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment
Sara G. Manore, Daniel Doheny, Grace L. Wong, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 171
Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation
Jinyun Dong, Xiangdong Cheng, Weidong Zhang, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 13, pp. 8884-8915
Closed Access | Times Cited: 148
JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies
Bilal Rah, Rafiq A. Rather, Gh Rasool Bhat, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 133
The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy
Manoj Garg, Muthu K. Shanmugam, Vipul Bhardwaj, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 3, pp. 1291-1336
Closed Access | Times Cited: 115
A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance
Qiyao Zheng, Hui Dong, Jianshan Mo, et al.
Theranostics (2020) Vol. 11, Iss. 2, pp. 824-840
Open Access | Times Cited: 76
STAT3-mediated osteogenesis and osteoclastogenesis in osteoporosis
Xiaoli Hou, Faming Tian
Cell Communication and Signaling (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 44
Development of new thieno[2,3-d]pyrimidines as dual EGFR and STAT3 inhibitors endowed with anticancer and pro-apoptotic activities
Heba A. Elsebaie, Tarek F. El‐Moselhy, Eman A. El-Bastawissy, et al.
Bioorganic Chemistry (2024) Vol. 143, pp. 107101-107101
Closed Access | Times Cited: 15
Unveiling the potential of isatin-grafted phenyl-1,2,3-triazole derivatives as dual VEGFR-2/STAT-3 inhibitors: Design, synthesis and biological assessments
Heba A. Elsebaie, Maha-Hamadien Abdulla, Zainab M. Elsayed, et al.
Bioorganic Chemistry (2024) Vol. 151, pp. 107626-107626
Closed Access | Times Cited: 9
Signal transducer and activator of transcription 3 signaling in tumor immune evasion
Luying Zhang, Kamil Kuča, You Li, et al.
Pharmacology & Therapeutics (2021) Vol. 230, pp. 107969-107969
Closed Access | Times Cited: 48
CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression
Hong‐Yong Cui, Shijie Wang, Fei Song, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 47
Targeting the STAT3 oncogenic pathway: Cancer immunotherapy and drug repurposing
Yushan Dong, Jingyu Chen, Yuhan Chen, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115513-115513
Open Access | Times Cited: 21
Identification of marine natural product Pretrichodermamide B as a STAT3 inhibitor for efficient anticancer therapy
Rui Li, Yue Zhou, Xinxin Zhang, et al.
Marine Life Science & Technology (2023) Vol. 5, Iss. 1, pp. 94-101
Open Access | Times Cited: 17
Targeting the STAT3 pathway with STAT3 degraders
Zhijie Wang, Xiaotong Liao, Haiqi He, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 9, pp. 811-823
Closed Access | Times Cited: 7
A large-scale transcriptional analysis reveals herb-derived ginsenoside F2 suppressing hepatocellular carcinoma via inhibiting STAT3
Xue Tan, Xiaofang Ma, Yifei Dai, et al.
Phytomedicine (2023) Vol. 120, pp. 155031-155031
Closed Access | Times Cited: 13
Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024)
Zhaoyong Kang, Li Shen, Yan Li, et al.
Chinese Chemical Letters (2024), pp. 110447-110447
Closed Access | Times Cited: 5
The STAT family: Key transcription factors mediating crosstalk between cancer stem cells and tumor immune microenvironment
Mengxuan Zhu, Suyao Li, Xin Cao, et al.
Seminars in Cancer Biology (2022) Vol. 88, pp. 18-31
Closed Access | Times Cited: 21
Exploration of novel isoxazole-fused quinone derivatives as anti-colorectal cancer agents through inhibiting STAT3 and elevating ROS level
Lidan Zhang, Pingxian Liu, Yunhan Jiang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116448-116448
Closed Access | Times Cited: 4
New findings on the antagonism of the environmental chemical toxicity 2-ethylhexyl diphenyl phosphate: Glycyrrhizic Acid as an Nrf2 activator targets Nrf2/ROS/STAT3 signalling crosstalk to alleviate thymic injury in chicks
Linghuan Luo, Ming Ge, Yiming Sun, et al.
Poultry Science (2025) Vol. 104, Iss. 4, pp. 104918-104918
Open Access
Natural STAT3 inhibitors: A mini perspective
Zhuo Wang, Chunngai Hui, Yusheng Xie
Bioorganic Chemistry (2021) Vol. 115, pp. 105169-105169
Closed Access | Times Cited: 27
Curcumin inhibits the viability, migration and invasion of papillary thyroid cancer cells by regulating the miR‑301a‑3p/STAT3 axis
Ying Liang, Deyu Kong, Yi Zhang, et al.
Experimental and Therapeutic Medicine (2021) Vol. 22, Iss. 2
Open Access | Times Cited: 24
JAK-STAT signaling pathway in non-infectious uveitis
Yuhan Su, Tianyu Tao, Xiuxing Liu, et al.
Biochemical Pharmacology (2022) Vol. 204, pp. 115236-115236
Closed Access | Times Cited: 18
Selenoprotein S: A versatile disordered protein
Farid Ghelichkhani, Fabio González, Mariia A. Kapitonova, et al.
Archives of Biochemistry and Biophysics (2022) Vol. 731, pp. 109427-109427
Open Access | Times Cited: 17
Enzyme-Dynamic Extracellular Vesicles for Metalloimmunotherapy of Malignant Pleural Effusions
Jiexin Li, Ruiqi Yang, Fuqiang Dong, et al.
ACS Nano (2024) Vol. 18, Iss. 33, pp. 21855-21872
Closed Access | Times Cited: 3
Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?
Kyli Berkley, Julian Zalejski, Ashutosh Sharma
Cancers (2025) Vol. 17, Iss. 5, pp. 755-755
Open Access
Page 1 - Next Page

Scroll to top